Comparing the current results to its competitors, Cytomx Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -79.85 %, despite the revenue increase by the most of its competitors of 19.81 %, recorded in the same quarter.
Cytomx Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 166 %
Cytomx Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and biopharmaceutical industries, facing competition in antibody-drug conjugates (ADC), T cell engagers (TCE), and immuno-oncology therapeutics. Competitors include large biopharmaceutical firms, specialty biotechnology companies, academic research departments, and public and private research institutions. Companies involved in antibody masking and conditional activation strategies include AbbVie, Adagene, Amgen, BioAtla, Halozyme Therapeutics, Merck, Roche, Sanofi, Takeda Pharmaceutical, Werewolf Therapeutics, Janux Therapeutics, Xilio Therapeutics, and Vir Biotechnology. In the antibody-drug conjugates sector, competitors include AbbVie, Daiichi Sankyo, Gilead Sciences, Pfizer, Roche, and Merck. Other competitors identified in company filings are Daiichi Sankyo, Gilead Sciences, Janux Therapeutics, Pfizer, and Werewolf Therapeutics.
April 3, 2024
San Francisco-based biopharmaceutical company CytomX Therapeutics has proudly announced their nomination of the second clinical candidate in its Broad PROBODY T-Cell Engaging Bispecific (TCB) collaboration with Astellas. This comes as the third milestone in the ongoing collaboration between the two companies, bringing the total accomplishment value to $5 million in acquired milestone payments.CytomX Therapeutics is well-known for its dedication towards developing efficacious treatments for patients with cancer by leveraging novel drug class of therapeutics using its Probody technology. This second clinical candidate delivers additional reinforcement to the robust and expanding development efforts of the comp...
Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Cytomx Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cytomx Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
